Novartis AG (NVS) — closed signal from September 24, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 23, 2025 — +13.4% at the close.
Predicted vs. what happened
What happened
Reached its target in 82 days.
The thesis — published September 24, 2025
Novartis looks set for a rebound after a rough patch. Fresh ARTIOS study results make its multiple sclerosis drug Kesimpta look stronger, and a plan to spend $23B building in the U.S. can help reduce tariff worries. There are early signs that more buyers are stepping in, but the recent average price is still drifting down, so patience helps. Over the next 0-3 months, a move back toward past price ranges seems realistic, with currency and pricing risks.
Primary drivers
- New study results make Kesimpta look stronger for relapsing MS care
- Planned $23B U.S. build-out could cut tariff risks and delays
- Shares fell hard, now signs of buying interest are reappearing
- Large, steady pharma that can hold up better in weak markets
How it played out
NVS: target reached in 82 days
Lyra published NVS on 2025-09-24 at $122.67, with a short-term thesis for 10% growth. The thesis pointed to stronger Kesimpta study results, a planned $23B U.S. build-out, renewed buying interest after a hard fall, and the steadier profile of a large pharma business. It also noted currency and pricing risks.
Inside the window, NVS reached a peak of $140.18 on 2025-12-23, above the $134.93 target. The target was reached in 82 days. The stock ended at $139.13, with a peak gain of 14.3%. The thesis played out.
What happened during the window
On 2025-10-26, Novartis agreed to acquire Avidity Biosciences for about $12 billion in cash. On 2025-10-28, Novartis reported third-quarter revenue of $13.91 billion and reaffirmed its full-year outlook.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.